Analyzing NovaBay Pharmaceuticals (NBY) and Celyad SA (CYAD)

NovaBay Pharmaceuticals (NYSE: NBY) and Celyad SA (NASDAQ:CYAD) are both small-cap biotechnology & medical research – nec companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for NovaBay Pharmaceuticals and Celyad SA, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NovaBay Pharmaceuticals 0 1 4 0 2.80
Celyad SA 0 0 1 0 3.00

NovaBay Pharmaceuticals presently has a consensus price target of $6.75, suggesting a potential upside of 60.71%. Celyad SA has a consensus price target of $74.00, suggesting a potential upside of 38.34%. Given NovaBay Pharmaceuticals’ higher probable upside, research analysts plainly believe NovaBay Pharmaceuticals is more favorable than Celyad SA.

Insider & Institutional Ownership

3.4% of Celyad SA shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

NovaBay Pharmaceuticals has a beta of -0.69, indicating that its share price is 169% less volatile than the S&P 500. Comparatively, Celyad SA has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500.


This table compares NovaBay Pharmaceuticals and Celyad SA’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NovaBay Pharmaceuticals -42.16% -184.30% -56.33%
Celyad SA N/A N/A N/A

Earnings & Valuation

This table compares NovaBay Pharmaceuticals and Celyad SA’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
NovaBay Pharmaceuticals N/A N/A N/A ($0.83) -5.06
Celyad SA $9.43 million 55.93 -$26.12 million N/A N/A

NovaBay Pharmaceuticals has higher revenue, but lower earnings than Celyad SA.


Celyad SA beats NovaBay Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc., formerly NovaCal Pharmaceuticals, Inc., is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. It develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The Company’s dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product.

About Celyad SA

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle. C-Cure consists of autologous adult stem cells guided in vitro to the cardiac lineage before implantation in the failing heart. Furthermore, the Company is involved in the field of immuno-oncology, through its subsidiary, OnCyte.

Receive News & Ratings for NovaBay Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.

Leave a Reply